论文部分内容阅读
本文用米托蒽醌和足叶乙甙联合(ME方案)治疗各型急性白血病患者34例,其中初次接受化疗者(初治组)13例,复治组21例。结果:初治组完全缓解率为46%,部分缓解率为23%,总有效率为69%。复治组完全缓解率为33%,部分缓解率为24%,总有效率为57%。ME方案主要副作用为骨髓抑制,其它非血液学副作用可以耐受。初步结果认为ME联合应用可以作为难治性或复发性白血病的一种选择性治疗方案。
In this paper, mitoxantrone and etoposide (ME regimen) in the treatment of 34 patients with various types of acute leukemia, including initial chemotherapy (initial treatment group) in 13 cases, retreatment group 21 cases. Results: The initial remission group was 46% complete remission rate was 23%, the total effective rate was 69%. The complete remission group was 33%, the partial remission rate was 24% and the total effective rate was 57%. The main side effect of ME regimen is myelosuppression, and other non-hematologic side effects can be tolerated. The preliminary results suggest that the combination of ME can be used as a selective treatment of refractory or recurrent leukemia.